There were no significant differences in the frequencies of total B cells (CD19+) or plasmablasts (CD19+ CD24- CD38hi) between T1D, T2D and controls (10.87 ± 4.56 and 1.07 ± 0.42 in T1D patients, 9.17 ± 4.3 and 1.00 ± 0.44 in T2D patents, 9.20 ± 4.4 and 1.03 ± 0.39 in healthy controls for total B cells and plasmablasts, respectively). This evidence concerns the gene CD19 and type 2 diabetes mellitus.